Bookmark
Forward
QuickView for Simvastatin (compound)
PubChem
| Name: | Simvastatin |
|---|---|
| PubChem Compound ID: | 11166019 |
| Description: | A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL. |
| Molecular formula: | C25H38O5 |
| Molecular weight: | 418.566 g/mol |
DrugBank
Identification
| Name: | Simvastatin |
|---|---|
| Name (isomeric): | DB00641 |
| Drug Type: | small molecule |
| Description: | A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL. |
| Synonyms: |
Simvastatine [French]; Simvastatin [Usan:Ban:Inn]; Simvastatinum [Latin]; Simvastatina [Spanish]
|
| Brand: | Nivelipol, Zocord, Colemin, Sivastin, Lipex, Corolin, Denan, Pantok, Simovil, Vasotenal, Labistatin, Synvinolin, Sinvacor, Cholestat, Coledis, Lodales, Medipo, Zocor, Rendapid |
| Brand name mixture: | Inegy(Simvastatin + Ezetimibe), Vytorin(Simvastatin + Ezetimibe) |
| Category: | Antilipemic Agents, Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| CAS number: | 79902-63-9 |
Pharmacology
| Indication: | For the treatment of hypercholesterolemia. |
|---|---|
| Pharmacology: | Simvastatin, the methylated form of lovastatin, is an oral antilipemic agent which inhibits HMG-CoA reductase. simvastatin is used in the treatment of primary hypercholesterolemia and is effective in reducing total and LDL-cholesterol as well as plasma triglycerides and apolipoprotein B. |
| Mechanism of Action: |
The 6-membered lactone ring of simvastatin is hydrolyzed in vivo to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme redu...
show more » |
| Absorption: | Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues. |
| Protein binding: | Both simvastatin and its b-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins. |
| Biotransformation: | Hepatic, simvastatin is a substrate for CYP3A4. |
| Route of elimination: | Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces. |
| Half Life: | 3 hours |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Enzymes
Transporters
